Skip to main content
Premium Trial:

Request an Annual Quote

As Expected, Nasdaq Issues Sequenom Delisting Notice

NEW YORK, March 22 (GenomeWeb News) - As expected, the Nasdaq exchange has notified Sequenom that its common stock is now subject to delisting due to its noncompliance with the exchange's $1.00 minimum closing bid price requirement, the company said today.


The notice comes less than a week after Sequenom was unable to meet its Nasdaq-imposed minimum requirement for continued listing when it failed to lift its shares above $1 for at least 10 consecutive trading days over the past six months.


Sequenom said that it plans to request a hearing before the Nasdaq Listing Qualifications Panel to review the determination to delist its common stock and to seek continued listing of its common stock on Nasdaq. The hearing is expected to be scheduled within 30 to 45 days of the request, Sequenom said. Sequenom will remain listed on the exchange during the appeal process.


As GenomeWeb News reported last September, the company had until March 15 to comply with the minimum bid requirement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more